Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Rhodes, Lyndsay V ^a   Antoon, James W ^a   Muir, Shannon E ^a   Elliott, Steven ^a   Beckman, Barbara S ^a   Burow, Matthew E ^a,b  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYTOKINE; ESTROGEN RECEPTOR; GREEN FLUORESCENT PROTEIN; GROWTH FACTOR; PLERIXAFOR; PROGESTERONE RECEPTOR; STROMAL CELL DERIVED FACTOR 1; HETEROCYCLIC COMPOUND;

ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; BREAST CARCINOMA; CARCINOMA CELL; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CELL SECRETION; CELL STRAIN MCF 7; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; GENE EXPRESSION; GENETIC LINKAGE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; METASTASIS; MOLECULAR INTERACTION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; BREAST TUMOR; CARCINOMA; CELL CULTURE; CELL DIFFERENTIATION; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CARCINOMA; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CXCL12; COCULTURE TECHNIQUES; FEMALE; FLOW CYTOMETRY; HETEROCYCLIC COMPOUNDS; HUMANS; MESENCHYMAL STEM CELLS; MICROSCOPY, FLUORESCENCE; RECEPTORS, CXCR4; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 78349245224     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-295     Document Type: Article

References (92)

1. Ali S, Coombes RC. Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia 2000, 5:271-281. 10.1023/A:1009594727358, 14973389.
2. Jordan VC, Gottardis MM, Robinson SP, Friedl A. Immune-deficient animals to study "hormone-dependent" breast and endometrial cancer. J Steroid Biochem 1989, 34:169-176. 10.1016/0022-4731(89)90079-4, 2626014.
3. Brodie A, Sabnis G, Jelovac D. Aromatase and breast cancer. J Steroid Biochem Mol Biol 2006, 102:97-102. 10.1016/j.jsbmb.2006.09.002, 1868399, 17113978.
4. Jordan VC. Long-term tamoxifen therapy to control or to prevent breast cancer: laboratory concept to clinical trials. Prog Clin Biol Res 1988, 262:105-123.
5. Reed MJ. The role of aromatase in breast tumors. Breast Cancer Res Treat 1994, 30:7-17. 10.1007/BF00682737, 7949206.
6. Wakeling AE, Bowler J. ICI 182,780, a new antioestrogen with clinical potential. J Steroid Biochem Mol Biol 1992, 43:173-177. 10.1016/0960-0760(92)90204-V, 1525058.
7. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 2003, 22:7316-7339. 10.1038/sj.onc.1206937, 14576841.
8. Clarke R, Skaar TC, Bouker KB, Davis N, Lee YR, Welch JN, Leonessa F. Molecular and pharmacological aspects of antiestrogen resistance. J Steroid Biochem Mol Biol 2001, 76:71-84. 10.1016/S0960-0760(00)00193-X, 11384865.
9. Kuske B, Naughton C, Moore K, Macleod KG, Miller WR, Clarke R, Langdon SP, Cameron DA. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models. Endocr Relat Cancer 2006, 13:1121-1133. 10.1677/erc.1.01257, 17158758.
10. Garcia M, Derocq D, Freiss G, Rochefort H. Activation of estrogen receptor transfected into a receptor-negative breast cancer cell line decreases the metastatic and invasive potential of the cells. Proc Natl Acad Sci USA 1992, 89:11538-11542. 10.1073/pnas.89.23.11538, 50587, 1454845.
11. van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, Look MP, Smid M, Veldscholte J, Sleijfer S, Foekens JA, Dorssers LC. Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol 2009, 27:542-549. 10.1200/JCO.2008.17.1462, 19075277.
12. (EBCTCG) EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. 10.1016/S0140-6736(05)66544-0, 15894097.
13. Larionov AA, Miller WR. Challenges in defining predictive markers for response to endocrine therapy in breast cancer. Future Oncol 2009, 5:1415-1428. 10.2217/fon.09.113, 19903069.
14. Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009, 9:631-643. 10.1038/nrc2713, 19701242.
15. Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, Sing T, Evans DB, Dixon JM. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol 2009, 27:1382-1387. 10.1200/JCO.2008.16.8849, 19224856.
16. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004, 432:332-337. 10.1038/nature03096, 15549095.
17. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
18. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, Weinberg RA. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348. 10.1016/j.cell.2005.02.034, 15882617.
19. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer 2001, 1:46-54. 10.1038/35094059, 2975572, 11900251.
20. Hu M, Polyak K. Molecular characterisation of the tumour microenvironment in breast cancer. Eur J Cancer 2008, 44:2760-2765. 10.1016/j.ejca.2008.09.038, 2729518, 19026532.
21. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001, 411:375-379. 10.1038/35077241, 11357145.
22. Hasebe T, Sasaki S, Sugitoh M, Ono M, Saitoh N, Ochiai A. Highly proliferative intratumoral fibroblasts and a high proliferative microvessel index are significant predictors of tumor metastasis in T3 ulcerative-type colorectal cancer. Hum Pathol 2001, 32:401-409. 10.1053/hupa.2001.23915, 11331957.
23. Kuniyasu H, Abbruzzese JL, Cleary KR, Fidler IJ. Induction of ductal and stromal hyperplasia by basic fibroblast growth factor produced by human pancreatic carcinoma. Int J Oncol 2001, 19:681-685.
24. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986, 315:1650-1659. 10.1056/NEJM198612253152606, 3537791.
25. Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res 2006, 66:9054-9064. 10.1158/0008-5472.CAN-05-3759, 16982747.
26. Hombauer H, Minguell JJ. Selective interactions between epithelial tumour cells and bone marrow mesenchymal stem cells. Br J Cancer 2000, 82:1290-1296. 10.1054/bjoc.1999.1093, 2374484, 10755403.
27. Ritter E, Perry A, Yu J, Wang T, Tang L, Bieberich E. Breast cancer cell-derived fibroblast growth factor 2 and vascular endothelial growth factor are chemoattractants for bone marrow stromal stem cells. Ann Surg 2008, 247:310-314. 10.1097/SLA.0b013e31816401d5, 18216538.
28. Schichor C, Birnbaum T, Etminan N, Schnell O, Grau S, Miebach S, Aboody K, Padovan C, Straube A, Tonn JC, Goldbrunner R. Vascular endothelial growth factor A contributes to glioma-induced migration of human marrow stromal cells (hMSC). Exp Neurol 2006, 199:301-310. 10.1016/j.expneurol.2005.11.027, 16574102.
29. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 276:71-74. 10.1126/science.276.5309.71, 9082988.
30. Haynesworth SE, Baber MA, Caplan AI. Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. Bone 1992, 13:69-80. 10.1016/8756-3282(92)90363-2, 1316137.
31. Mackay AM, Beck SC, Murphy JM, Barry FP, Chichester CO, Pittenger MF. Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng 1998, 4:415-428. 10.1089/ten.1998.4.415, 9916173.
32. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147. 10.1126/science.284.5411.143, 10102814.
33. Qiao C, Xu W, Zhu W, Hu J, Qian H, Yin Q, Jiang R, Yan Y, Mao F, Yang H, et al. Human mesenchymal stem cells isolated from the umbilical cord. Cell Biol Int 2008, 32:8-15. 10.1016/j.cellbi.2007.08.002, 17904875.
34. Paget S. The Distribution of Secondary Growths in Cancer of the Breast. The Lancet 1889, 133:571-573.
35. Corcoran KE, Trzaska KA, Fernandes H, Bryan M, Taborga M, Srinivas V, Packman K, Patel PS, Rameshwar P. Mesenchymal stem cells in early entry of breast cancer into bone marrow. PLoS ONE 2008, 3:e2563. 10.1371/journal.pone.0002563, 2430536, 18575622.
36. Molloy AP, Martin FT, Dwyer RM, Griffin TP, Murphy M, Barry FP, O'Brien T, Kerin MJ. Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int J Cancer 2009, 124:326-332. 10.1002/ijc.23939, 19003962.
37. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, Marx JC, Pyeritz RE, Brenner MK. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999, 5:309-313. 10.1038/6529, 10086387.
38. Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A, Battula VL, Weil M, Andreeff M, Marini FC. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009, 27:2614-2623. 10.1002/stem.187, 19650040.
39. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002, 62:3603-3608.
40. Djouad F, Bony C, Apparailly F, Louis-Plence P, Jorgensen C, Noel D. Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation 2006, 82:1060-1066. 10.1097/01.tp.0000236098.13804.0b, 17060855.
41. Haynesworth SE, Baber MA, Caplan AI. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol 1996, 166:585-592. 10.1002/(SICI)1097-4652(199603)166:3<585::AID-JCP13>3.0.CO;2-6, 8600162.
42. Hall B, Andreeff M, Marini F. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol 2007, 263-283. full_text, 17554513.
43. Stich S, Haag M, Haupl T, Sezer O, Notter M, Kaps C, Sittinger M, Ringe J. Gene expression profiling of human mesenchymal stem cells chemotactically induced with CXCL12. Cell Tissue Res 2009, 336:225-236. 10.1007/s00441-009-0768-z, 19296133.
44. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006, 5:1597-1601. 10.4161/cc.5.15.3112, 16880743.
45. Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Salvo VA, Fonseca JP, Lacey MR, et al. Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res Treat 121:293-300. 10.1007/s10549-009-0458-2, 19597705.
46. Hall JM, Korach KS. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 2003, 17:792-803. 10.1210/me.2002-0438, 12586845.
47. Sauve K, Lepage J, Sanchez M, Heveker N, Tremblay A. Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway. Cancer Res 2009, 69:5793-5800. 10.1158/0008-5472.CAN-08-4924, 19584281.
48. Fierro FA, Sierralta WD, Epunan MJ, Minguell JJ. Marrow-derived mesenchymal stem cells: role in epithelial tumor cell determination. Clin Exp Metastasis 2004, 21:313-319. 10.1023/B:CLIN.0000046130.79363.33, 15554387.
49. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563. 10.1038/nature06188, 17914389.
50. Rhodes LV, Burow ME. Human mesenchymal stem cells as mediators of breast carcinoma tumorigenesis and progression. TheScientificWorldJOURNAL 2010, 10:1084-1087.
51. Hwang JH, Shim SS, Seok OS, Lee HY, Woo SK, Kim BH, Song HR, Lee JK, Park YK. Comparison of cytokine expression in mesenchymal stem cells from human placenta, cord blood, and bone marrow. J Korean Med Sci 2009, 24:547-554. 10.3346/jkms.2009.24.4.547, 2719209, 19654931.
52. Sengupta S, Schiff R, Katzenellenbogen BS. Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells. Breast Cancer Res Treat 2009, 117:243-251. 10.1007/s10549-008-0186-z, 2728144, 18807177.
53. Mishra PJ, Mishra PJ, Glod JW, Banerjee D. Mesenchymal stem cells: flip side of the coin. Cancer Res 2009, 69:1255-1258. 10.1158/0008-5472.CAN-08-3562, 19208837.
54. Prockop DJ, Olson SD. Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions. Blood 2007, 109:3147-3151. 10.1182/blood-2006-03-013433, 1852233, 17170129.
55. Sasser AK, Mundy BL, Smith KM, Studebaker AW, Axel AE, Haidet AM, Fernandez SA, Hall BM. Human bone marrow stromal cells enhance breast cancer cell growth rates in a cell line-dependent manner when evaluated in 3D tumor environments. Cancer Lett 2007, 254:255-264. 10.1016/j.canlet.2007.03.012, 17467167.
56. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, Andreeff M, Marini F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009, 4:e4992. 10.1371/journal.pone.0004992, 2661372, 19352430.
57. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007, 211:27-35. 10.1002/jcp.20959, 17226788.
58. Block GJ, Ohkouchi S, Fung F, Frenkel J, Gregory C, Pochampally R, Dimattia G, Sullivan DE, Prockop DJ. Multipotent Stromal Cells (MSCs) are Activated to Reduce Apoptosis in Part by Upregulation and Secretion of Stanniocalcin-1 (STC-1). Stem Cells 2009, 27:670-681.
59. Martin FT, Dwyer RM, Kelly J, Khan S, Murphy JM, Curran C, Miller N, Hennessy E, Dockery P, Barry FP, et al. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res Treat 2010, 124:317-326. 10.1007/s10549-010-0734-1, 20087650.
60. Leonessa F, Boulay V, Wright A, Thompson EW, Brunner N, Clarke R. The biology of breast tumor progression. Acquisition of hormone independence and resistance to cytotoxic drugs. Acta Oncol 1992, 31:115-123. 10.3109/02841869209088890, 1622625.
61. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973, 51:1409-1416.
62. Fiedler J, Leucht F, Waltenberger J, Dehio C, Brenner RE. VEGF-A and PlGF-1 stimulate chemotactic migration of human mesenchymal progenitor cells. Biochem Biophys Res Commun 2005, 334:561-568. 10.1016/j.bbrc.2005.06.116, 16005848.
63. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56. 10.1038/35065016, 11242036.
64. Cristino S, Piacentini A, Manferdini C, Codeluppi K, Grassi F, Facchini A, Lisignoli G. Expression of CXC chemokines and their receptors is modulated during chondrogenic differentiation of human mesenchymal stem cells grown in three-dimensional scaffold: evidence in native cartilage. Tissue Eng Part A 2008, 14:97-105. 10.1089/ten.a.2007.0121, 18333808.
65. Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol 2008, 28:1950-1959. 10.1161/ATVBAHA.107.161224, 18818421.
66. Dewan MZ, Ahmed S, Iwasaki Y, Ohba K, Toi M, Yamamoto N. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother 2006, 60:273-276. 10.1016/j.biopha.2006.06.004, 16828253.
67. Gelmini S, Mangoni M, Serio M, Romagnani P, Lazzeri E. The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis. J Endocrinol Invest 2008, 31:809-819.
68. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker GD. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004, 64:8604-8612. 10.1158/0008-5472.CAN-04-1844, 15574767.
69. Akekawatchai C, Holland JD, Kochetkova M, Wallace JC, McColl SR. Transactivation of CXCR4 by the insulin-like growth factor-1 receptor (IGF-1R) in human MDA-MB-231 breast cancer epithelial cells. J Biol Chem 2005, 280:39701-39708. 10.1074/jbc.M509829200, 16172123.
70. Arya M, Ahmed H, Silhi N, Williamson M, Patel HR. Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration. Tumour Biol 2007, 28:123-131. 10.1159/000102979, 17510563.
71. Du YF, Shi Y, Xing YF, Zeng FQ. Establishment of CXCR4-small interfering RNA retrovirus vector driven by human prostate-specific antigen promoter and its biological effects on prostate cancer in vitro and in vivo. J Cancer Res Clin Oncol 2008, 134:1255-1264. 10.1007/s00432-008-0394-2, 18431597.
72. Epstein RJ. The CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer 2004, 4:901-909. 10.1038/nrc1473, 15516962.
73. He X, Fang L, Wang J, Yi Y, Zhang S, Xie X. Bryostatin-5 blocks stromal cell-derived factor-1 induced chemotaxis via desensitization and down-regulation of cell surface CXCR4 receptors. Cancer Res 2008, 68:8678-8686. 10.1158/0008-5472.CAN-08-0294, 18974109.
74. Holm NT, Abreo F, Johnson LW, Li BD, Chu QD. Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC). Breast Cancer Res Treat 2009, 113:293-299. 10.1007/s10549-008-9921-8, 18270814.
75. Juarez J, Bendall L, Bradstock K. Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. Curr Pharm Des 2004, 10:1245-1259. 10.2174/1381612043452640, 15078139.
76. Lapteva N, Yang AG, Sanders DE, Strube RW, Chen SY. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 2005, 12:84-89. 10.1038/sj.cgt.7700770, 15472715.
77. Liang Z, Wu H, Reddy S, Zhu A, Wang S, Blevins D, Yoon Y, Zhang Y, Shim H. Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Biochem Biophys Res Commun 2007, 363:542-546. 10.1016/j.bbrc.2007.09.007, 17889832.
78. Richert MM, Vaidya KS, Mills CN, Wong D, Korz W, Hurst DR, Welch DR. Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone. Oncol Rep 2009, 21:761-767.
79. Burow ME, Weldon CB, Tang Y, Navar GL, Krajewski S, Reed JC, Hammond TG, Clejan S, Beckman BS. Differences in susceptibility to tumor necrosis factor alpha-induced apoptosis among MCF-7 breast cancer cell variants. Cancer Res 1998, 58:4940-4946.
80. Levenson AS, Jordan VC. MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res 1997, 57:3071-3078.
81. Villalobos M, Olea N, Brotons JA, Olea-Serrano MF, Ruiz de Almodovar JM, Pedraza V. The E-screen assay: a comparison of different MCF7 cell stocks. Environ Health Perspect 1995, 103:844-850. 10.2307/3432398, 1519213, 7498097.
82. Osborne CK, Hobbs K, Trent JM. Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat 1987, 9:111-121. 10.1007/BF01807363, 3620713.
83. Klotz DM, Castles CG, Fuqua SA, Spriggs LL, Hill SM. Differential expression of wild-type and variant ER mRNAs by stocks of MCF-7 breast cancer cells may account for differences in estrogen responsiveness. Biochem Biophys Res Commun 1995, 210:609-615. 10.1006/bbrc.1995.1702, 7755640.
84. Salvo VA, Boue SM, Fonseca JP, Elliott S, Corbitt C, Collins-Burow BM, Curiel TJ, Srivastav SK, Shih BY, Carter-Wientjes C, et al. Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis. Clin Cancer Res 2006, 12:7159-7164. 10.1158/1078-0432.CCR-06-1426, 17145841.
85. Sekiya I, Larson BL, Smith JR, Pochampally R, Cui JG, Prockop DJ. Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. Stem Cells 2002, 20:530-541. 10.1634/stemcells.20-6-530, 12456961.
86. Kill IR. Localisation of the Ki-67 antigen within the nucleolus. Evidence for a fibrillarin-deficient region of the dense fibrillar component. J Cell Sci 1996, 109:1253-1263.
87. Gnecchi M, Melo LG. Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium. Methods Mol Biol 2009, 482:281-294. full_text, 19089363.
88. Struckhoff AP, Bittman R, Burow ME, Clejan S, Elliott S, Hammond T, Tang Y, Beckman BS. Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J Pharmacol Exp Ther 2004, 309:523-532. 10.1124/jpet.103.062760, 14742741.
89. Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ, Reed MW. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem 2000, 285:194-204. 10.1006/abio.2000.4753, 11017702.
90. Tse C, Capeau J. [Real time PCR methodology for quantification of nucleic acids]. Ann Biol Clin (Paris) 2003, 61:279-293.
91. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45. 10.1093/nar/29.9.e45, 55695, 11328886.
92. Zimmermann MC, Tilghman SL, Boue SM, Salvo VA, Elliott S, Williams KY, Skripnikova EV, Ashe H, Payton-Stewart F, Vanhoy-Rhodes L, et al. Glyceollin I, a novel antiestrogenic phytoalexin isolated from activated soy. J Pharmacol Exp Ther 2010, 332:35-45. 10.1124/jpet.109.160382, 19797619.